Abcam completed the acquisition of BioVision for $340m.

Abcam, a provider of life science research tools, completed the acquisition of BioVision, an innovator and distributor of life science research tools to biopharma, diagnostic and academic customers, for $340m. "We know the BioVision business well, having been a major distributor of their products since 2003. This acquisition represents a compelling opportunity to secure a proven portfolio of high-quality products, including a leading portfolio of biochemical and cell-based assay kits, that will allow us to better serve customer needs. BioVision has sustained strong growth over many years and, together with Abcam’s brand, reach and capabilities, we are confident we are well positioned to build on this success and reinforce Abcam’s ability to serve life scientists globally," Alan Hirzel, Abcam CEO.